<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article134</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/TOPCAT" style="display:block; margin-bottom:10px;">TOPCAT Original</a></li>
<h2><strong>TOPCAT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>
<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does treatment with spironolactone improve the prognosis for patients with heart failure and a preserved left ventricular ejection fraction?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the composite primary outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for heart failure management.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Current guidelines offer no specific recommendations for the management of heart failure in patients with preserved ejection fraction, except for attention to coexisting conditions.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, international, randomized, double-blind, placebo-controlled trial<br/>
- N=3,445 patients with symptomatic heart failure and left ventricular ejection fraction ≥45%<br/>
- Spironolactone (15 to 45 mg daily) vs placebo<br/>
- Mean follow-up: 3.3 years<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion Criteria: Patients ≥50 years of age, with symptomatic heart failure, left ventricular ejection fraction ≥45%, hospitalization within the previous 12 months for heart failure management, or elevated natriuretic peptide levels.<br/>
- Exclusion Criteria: Severe systemic illness, severe renal dysfunction, various coexisting conditions and medications, and recent acute events.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Initial dose: 15 mg spironolactone or placebo once daily, increased to a maximum of 45 mg daily during the first 4 months after randomization.<br/>
- Subsequent dose adjustments as required with frequent monitoring for serum potassium and creatinine levels.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary Outcome: Composite of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for heart failure management.<br/>
- Secondary Outcome: Death from any cause, hospitalization for any cause, hyperkalemia, hypokalemia, elevated serum creatinine level.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- A significant proportion of participants discontinued the study drug, primarily due to elevations in serum creatinine and potassium levels.<br/>
- There were marked regional differences in event rates, which may reflect heterogeneity in coexisting conditions and practice patterns.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- The National Heart, Lung, and Blood Institute; contract HHSN268200425207C<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
